Editor’s note: This is a developing news story. Please check back soon for updates.
Alcon has acquired a majority interest in Aurion Biotech, according to a press release.
Aurion will operate as a separate company but will use support from Alcon to take AURN001, its clinical-stage allogeneic cell therapy for corneal edema secondary to endothelial disease, into phase 3 trials.
Aurion has completed enrollment and dosing in the phase 1/2 CLARA trial of AURN001, and study results from 97 subjects support the therapy’s advancement into phase 3 development, according to the release.
Along